An early FDA approval is a bonus for any drug. But for Pfizer's new breast cancer drug Ibrance (palbociclib), the earlier-than-expected green light has given it a billion-dollar-plus boost--on paper, anyway.
Move over, Sovaldi--there's a new launch king in town. And luckily for Gilead, it's another of its own. Harvoni has officially unseated its hep C predecessor, putting up $2.11 billion in revenue in its first quarter on the U.S. market. While that's less than Sovaldi recorded in Q1 of last year--it posted $2.27 billion in sales--Harvoni's Oct. 10 approval meant it missed two weeks of Q4 sales time. Read more >>
Drugmakers should behave better. Drugmakers should absolutely follow the rules, and yes, drugmakers should behave as if they have a conscience. But if the public opinon scales are stacked against pharma's image, then the behavior scales are balanced away from Jiminy Cricket. With share price and earnings as the goals, incentives are leading in the opposite direction. Read more >>
Salix may have just agreed to sell itself to Valeant, a company known for squeezing every penny out of its acquisitions. But never fear, specialty sales reps: CEO J. Michael Pearson says you're safe.
Shire is pushing full steam ahead to get the word out on binge eating disorder, the new indication it snagged for blockbuster Vyvanse last month. But some doctors think the Dublin drugmaker may be taking the marketing a bit too far, considering Vyvanse's abuse potential.
Eli Lilly's long-acting basal insulin peglispro is on the back burner now. Some analysts figure it's well on its way to being canned. But the news isn't quite as bad for Lilly as one might expect--nor quite as good for the drug peglispro was hoping to challenge, Sanofi's Lantus.
Which launches are the ones to watch? That can vary depending on who you're talking to. But as Bloomberg Intelligence recently found, industry members and healthcare investors have some similar ideas this year--and unsurprisingly, they've got their eyes on Gilead's Harvoni.
Here's a new threat to Lucentis, the eye drug from Roche and Novartis. British doctors are calling for the National Health Service to routinely use Roche's cancer med Avastin to treat patients with wet age-related macular degeneration, rather than the much costlier Lucentis.
Flush with success in negotiating discounts for hepatitis C drugs, payers are promising to strong-arm drugmakers in other treatment classes, too--cholesterol and cancer, for instance. They'll have more than one oncologist on their sides: A top doctor at the MD Anderson Cancer Center, fed up with cancer drug prices, plans a social media protest.